Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma - Scorecard - MDSpire

Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma

  • By

  • Yiming Zhao

  • Lixia Liu

  • Wei Qian

  • Jianjun Li

  • Liang Xia

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy and Safety Comparison of Etoposide Combined with PEG-rhG-CSF Versus Etoposide with G-CSF for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma and Lymphoma Patients

At a Glance

CategoryDetail
Condition
Key MechanismsHigh-dose etoposide (VP-16) combined with PEG-rhG-CSF or rhG-CSF for stem cell mobilisation, highlighting comparative efficacy.
Target Population
Care Setting

Key Highlights

  • Add safety profile details regarding adverse events.

Guideline-Based Recommendations

Diagnosis

  • Include specific diagnostic criteria for multiple myeloma and lymphoma.

Management

    Monitoring & Follow-up

    • Add recommendations for monitoring during treatment.

    Risks

      Patient & Prescribing Data

      Include specific data or statistics from the study.

      Clinical Best Practices

      • monitoring

      Related Resources & Content

        Original Source(s)

        Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma

        • by Yiming Zhao, Lixia Liu, Wei Qian, Jianjun Li, Liang Xia

        • June 17, 2026

        Related Content

        The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer

        Differential expression of immune activation markers in T cells from patients with multiple myeloma

        HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells